Parameter | Cutoff | Univariate | Multivariate | ||
---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Age (years) | Continuous | 1.02 (0.99–1.04) per score | 0.19 | ||
Sex | Male | Reference | 0.43 | ||
Female | 0.78 (0.41–1.39) | ||||
ECOG PS | 0 | Reference | 0.011* | Reference | 0.0074* |
≥ 1 | 1.93 (1.15–3.18) | 2.09 (1.20–3.57) | |||
eGFR (mL/min/1.73 m2) | < 60 | Reference | 0.52 | ||
≥ 60 | 1.17 (0.71–1.92) | ||||
Primary site | Bladder | Reference | 0.17 | ||
Upper urinary tract | 1.06 (0.63–1.82) | ||||
Both | 1.85 (0.91–3.57) | ||||
Resection of primary site | No | Reference | 0.0043* | Reference | 0.079 |
Yes | 0.49 (0.30–0.80) | 0.64 (0.38–1.05) | |||
Prior neoadjuvant/adjuvant chemotherapy | No | Reference | 0.61 | ||
Yes | 1.20 (0.55–2.31) | ||||
Lymph node metastasis | No | Reference | 0.038* | Reference | 0.0032* |
Yes | 1.73 (1.05–2.95) | 2.28 (1.34–4.01) | |||
Lung metastasis | No | Reference | 0.62 | ||
Yes | 0.88 (0.53–1.44) | ||||
Bone metastasis | No | Reference | 0.71 | ||
Yes | 1.13 (0.56–2.84) | ||||
Liver metastasis | No | Reference | 0.014* | Reference | 0.0029* |
Yes | 2.20 (1.12–3.96) | 2.72 (1.35–5.09) | |||
First-line regimens | Full-dose GC | Reference | 0.73 | ||
Dose-reduced GC | 1.11 (0.59–2.03) | ||||
GCa | 1.25 (0.72–2.18) |